Cholecystokinin Antagonists in Gastroenterology

Guido Adler war ein österreichischer Musikwissenschaftler, Begründer der Wiener Musikwissenschaft und des Musikwissenschaftlichen Instituts der Universität Wien, dessen Leitung er bis 1927 übernahm. Das Musikwissenschaftliche Institut wurde zum Zentrum der österreichischen Musikforschung, von der Gesellschaft der Musikfreunde wurde Guido Adler zum Ehrenmitglied ernannt.

I: Biology of CCK.- Biochemistry of CCK.- The Morphological Localization of Cholecystokinin and Its Binding-Sites in the Diffuse Neuroendocrine System.- Heterogeneity of CCK Receptors: Classification and Characterization.- Biological Actions of CCK in the Gastrointestinal Tract.- Biological Actions of CCK in the Central Nervous System.- Vagally Mediated Actions of CCK.- II: Chemistry of CCK Antagonists.- Pentanoic Acid Derivatives.- Characterization of MK-329.- Boc-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-2-Phenylethyl Ester - JMV180: A Unique CCK Analogue with Different Actions on High- and Low-Affinity CCK Receptors.- III: Physiological Application of CCK Antagonists.- Cholestokinin Receptor Antagonists In Vitro.- Effects of Cholecystokinin Receptor Antagonists in Animal Models.- Role of Cholecystokinin in Regulating Gallbladder Contraction and Pancreatic Secretion in Man: Studies with Loxiglumide.- Effect of MK-329 on Pancreatic Secretion in Man.- Regulation of Gallbladder Contraction and Gastric Emptying by the CCK Receptor Antagonist MK-329.- Regulation of CCK Release by Bile Acids.- Pyloric Cholecystokinin Receptors.- Effects of CCK Antagonists on Intestinal Motility in Dogs.- The Role of CCK and CCK Antagonists in Human Esophageal and Gastroduodenal Motility.- Regulation of Gastrointestinal and Colonic Transit by CCK Antagonists.- The Role of CCK in Tumor Growth.- IV: Clinical Potentials of CCK Antagonists.- Experimental Pancreatitis.- Cholecystokinin-Receptor Antagonists in Experimental Pancreatic Tumor Growth.- Efficient Treatment of Biliary Colics with Loxiglumide.- The Role of CCK in Chronic Constipation.- The Rational Use of CCK Antagonists in Irritable Bowel Syndrome.- Cholecystokinin, Cholecystokinin-Receptor Antagonists and the Sphincter of Oddi.